Abbisko Therapeutics announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment

Prolific Machines, a biotechnology company revolutionizing biologics manufacturing, announced today that it has been accepted into the U.S. Food and Drug Administration

Women's health innovator Evofem Biosciences, Inc. and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement

Novavax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19)

UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world's largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical

Zai Lab Limited today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC)

RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced the expansion of its strategic collaboration with Moffitt Cancer Center, a global leader in cancer care and research.

PharmAla Biotech Holdings Inc. a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally

Roche announced today that the FDA has approved the VENTANA® MET (SP44) RxDx Assay, the first companion diagnostic approved to aid in determining MET (also known as c-Met) protein expression in NSQ-NSCLC patients.

Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline.